首页 > 最新文献

Hepatology Forum最新文献

英文 中文
D-dimer is a prognostic marker for 1-year mortality in patients with chronic liver failure and hepatic encephalopathy. D 二聚体是慢性肝衰竭和肝性脑病患者 1 年死亡率的预后指标。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0065
Yi-Shan He, Su-Hua Yang, Ze-Yu Huang, Lin Lin, Xue-Cheng Tong, Hong Dai, Yuan Xue

Background and aim: Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver failure with poor outcomes. The present study aimed to evaluate the predictive values of D-dimer in patients with HE.

Materials and methods: Patients with chronic liver failure (CLF) and HE were enrolled. Univariate and multivariate logistic analysis was performed to investigate the risk factors for 1-year mortality of HE.

Results: During the first year after diagnosis, 39.2% (65/166) of the patients died. D-dimer was significantly higher in non-survivors (Z=2.617, p<0.01). Both D-dimer and international normalized ratio (INR) positively correlated with Child-Pugh and MELD scores, and negatively correlated with sodium (all p<0.01). Moreover, there was a negative relationship between D-dimer and HE grades (r=-0.168, p=0.031), while the relationship between INR and HE grades was not significant (r=0.083, p=0.289). Multivariate analysis showed that age (odds ratio (OR):1.035, 95% CI:1.004-1.067, p=0.03), D-dimer (OR=1.138, 95% CI:1.030-1.258, p=0.01), ALT (OR=1.012, 95% CI:1.001-1.022, p=0.03), and sodium (OR=0.920, 95% CI:0.858-0.986, p=0.02) were independent risk factors for 1-year mortality. Then, a new model Model(Age_DD_ALT_Na) incorporating age, D-dimer, ALT, and sodium was developed. AUROC of Model(Age_DD_ALT_Na) was 0.732, which was significantly higher than MELD and Child-Pugh scores (AUROC: 0.602 and 0.599, p=0.013 and 0.022).

Conclusion: D-dimer is a prognostic marker for 1-year mortality in patients with CLF and HE.

背景和目的:肝性脑病(HE)是肝衰竭的一种神经精神并发症,治疗效果不佳。本研究旨在评估 D-二聚体对 HE 患者的预测价值:研究对象为慢性肝衰竭(CLF)和肝性脑病患者。采用单变量和多变量逻辑分析法研究肝衰竭患者1年死亡率的风险因素:结果:确诊后第一年,39.2%(65/166)的患者死亡。非存活者的 D-二聚体明显更高(Z=2.617,p 结论:D-二聚体是一种预后指标:D-二聚体是CLF和HE患者1年死亡率的预后指标。
{"title":"D-dimer is a prognostic marker for 1-year mortality in patients with chronic liver failure and hepatic encephalopathy.","authors":"Yi-Shan He, Su-Hua Yang, Ze-Yu Huang, Lin Lin, Xue-Cheng Tong, Hong Dai, Yuan Xue","doi":"10.14744/hf.2023.2023.0065","DOIUrl":"10.14744/hf.2023.2023.0065","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver failure with poor outcomes. The present study aimed to evaluate the predictive values of D-dimer in patients with HE.</p><p><strong>Materials and methods: </strong>Patients with chronic liver failure (CLF) and HE were enrolled. Univariate and multivariate logistic analysis was performed to investigate the risk factors for 1-year mortality of HE.</p><p><strong>Results: </strong>During the first year after diagnosis, 39.2% (65/166) of the patients died. D-dimer was significantly higher in non-survivors (Z=2.617, p<0.01). Both D-dimer and international normalized ratio (INR) positively correlated with Child-Pugh and MELD scores, and negatively correlated with sodium (all p<0.01). Moreover, there was a negative relationship between D-dimer and HE grades (r=-0.168, p=0.031), while the relationship between INR and HE grades was not significant (r=0.083, p=0.289). Multivariate analysis showed that age (odds ratio (OR):1.035, 95% CI:1.004-1.067, p=0.03), D-dimer (OR=1.138, 95% CI:1.030-1.258, p=0.01), ALT (OR=1.012, 95% CI:1.001-1.022, p=0.03), and sodium (OR=0.920, 95% CI:0.858-0.986, p=0.02) were independent risk factors for 1-year mortality. Then, a new model Model(Age_DD_ALT_Na) incorporating age, D-dimer, ALT, and sodium was developed. AUROC of Model(Age_DD_ALT_Na) was 0.732, which was significantly higher than MELD and Child-Pugh scores (AUROC: 0.602 and 0.599, p=0.013 and 0.022).</p><p><strong>Conclusion: </strong>D-dimer is a prognostic marker for 1-year mortality in patients with CLF and HE.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"193-197"},"PeriodicalIF":1.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatopulmonary syndrome unveiled: Exploring pathogenesis, diagnostic approaches, and therapeutic strategies. 肝肺综合征揭秘:探索发病机制、诊断方法和治疗策略。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2025-01-01 DOI: 10.14744/hf.2024.2024.0001
Anusha Alam, Nazli Begum Ozturk, Filiz Akyuz

Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver cirrhosis that causes an oxygenation defect. Many patients are asymptomatic at diagnosis or may have non-specific symptoms such as dyspnea. Since the diagnostic criteria for HPS have been established, its prevalence has been better estimated. HPS is an important prognostic indicator for patients undergoing evaluation for liver transplant. The implementation of the Model for End-stage Liver Disease exception policy has improved the outcomes of HPS; however, the mortality remains high. Here, we discuss the pathophysiology, diagnostic criteria, and recent experimental studies in HPS.

肝肺综合征(HPS)是肝硬化引起氧合缺陷的肺部并发症。许多患者在诊断时无症状或可能有非特异性症状,如呼吸困难。由于HPS的诊断标准已经确立,其患病率已得到更好的估计。HPS是评估肝移植患者预后的重要指标。终末期肝病模型例外政策的实施改善了HPS的结果;然而,死亡率仍然很高。在此,我们讨论了HPS的病理生理学、诊断标准和最近的实验研究。
{"title":"Hepatopulmonary syndrome unveiled: Exploring pathogenesis, diagnostic approaches, and therapeutic strategies.","authors":"Anusha Alam, Nazli Begum Ozturk, Filiz Akyuz","doi":"10.14744/hf.2024.2024.0001","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0001","url":null,"abstract":"<p><p>Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver cirrhosis that causes an oxygenation defect. Many patients are asymptomatic at diagnosis or may have non-specific symptoms such as dyspnea. Since the diagnostic criteria for HPS have been established, its prevalence has been better estimated. HPS is an important prognostic indicator for patients undergoing evaluation for liver transplant. The implementation of the Model for End-stage Liver Disease exception policy has improved the outcomes of HPS; however, the mortality remains high. Here, we discuss the pathophysiology, diagnostic criteria, and recent experimental studies in HPS.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"29-33"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver disorders in substance abusers. 药物滥用者的肝脏疾病。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2025-01-01 DOI: 10.14744/hf.2024.2024.0012
George Sarin Zacharia, Anu Jacob

Substance use disorders are a global health problem with detrimental effects on one's health, wealth, and stealth. It includes the use of prescribed medications or the use of illicit drugs in excess amounts or for excess durations associated with complex neuropsychiatric and/or physical manifestations. It affects every organ in the body, and the liver is no exception to the deleterious effects of substance abuse. The mechanism of liver injury varies from agent to agent and may include direct toxic effects, oxidative stress, and inflammatory responses. The hepatic involvement ranges from asymptomatic liver enzyme elevation and fatty liver disease to hepatitis, liver failure, and cirrhosis. Alcohol, the most frequent agent implicated in substance use disorder, is also a prototype hepatotoxin, capable of inducing the whole spectrum of liver diseases. Cigarette smoke contains numerous harmful chemicals, including carcinogens, which can induce liver injury, fibrosis, and HCC. Cocaine, particularly in acute overdose, can result in ischemic hepato-necrosis, while it can also result in clinically inapparent transaminasemia. Marijuana and opiates, despite being associated with numerous deleterious effects, are rarely implicated in clinically apparent liver injury. Individuals with substance use disorder are also prone to viral hepatitis and hepatic insults secondary to hypotension, hypoxia, and other systemic ailments. Liver transplant candidacy in individuals with substance use disorder is a highly complex arena, with guidelines balancing abstinence requirements against evolving evidence on outcomes. This review article provides a thorough analysis of the hepatotoxic repercussions stemming from the agents commonly implicated in substance abuse disorders.

物质使用障碍是一个全球性的健康问题,对一个人的健康、财富和隐秘都有不利影响。它包括与复杂的神经精神和/或身体表现相关的过量或超长时间使用处方药或非法药物。它影响到身体的每一个器官,肝脏也不例外,药物滥用的有害影响。肝损伤的机制因药物而异,可能包括直接毒性作用、氧化应激和炎症反应。肝脏受累范围从无症状的肝酶升高和脂肪肝疾病到肝炎、肝功能衰竭和肝硬化。酒精是物质使用障碍中最常见的因素,也是一种典型的肝毒素,能够诱发各种肝脏疾病。香烟烟雾中含有许多有害化学物质,包括致癌物质,可引起肝损伤、纤维化和肝细胞癌。可卡因,特别是急性过量,可导致缺血性肝坏死,同时也可导致临床不明显的转氨血症。大麻和阿片类药物,尽管与许多有害影响有关,但很少涉及临床明显的肝损伤。有物质使用障碍的人也容易患病毒性肝炎和继发于低血压、缺氧和其他系统性疾病的肝损伤。药物使用障碍患者的肝移植候选是一个高度复杂的领域,指南需要平衡戒断要求和不断发展的结果证据。这篇综述文章提供了一个全面的分析,肝毒性反应源于药物滥用障碍中通常涉及的代理商。
{"title":"Liver disorders in substance abusers.","authors":"George Sarin Zacharia, Anu Jacob","doi":"10.14744/hf.2024.2024.0012","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0012","url":null,"abstract":"<p><p>Substance use disorders are a global health problem with detrimental effects on one's health, wealth, and stealth. It includes the use of prescribed medications or the use of illicit drugs in excess amounts or for excess durations associated with complex neuropsychiatric and/or physical manifestations. It affects every organ in the body, and the liver is no exception to the deleterious effects of substance abuse. The mechanism of liver injury varies from agent to agent and may include direct toxic effects, oxidative stress, and inflammatory responses. The hepatic involvement ranges from asymptomatic liver enzyme elevation and fatty liver disease to hepatitis, liver failure, and cirrhosis. Alcohol, the most frequent agent implicated in substance use disorder, is also a prototype hepatotoxin, capable of inducing the whole spectrum of liver diseases. Cigarette smoke contains numerous harmful chemicals, including carcinogens, which can induce liver injury, fibrosis, and HCC. Cocaine, particularly in acute overdose, can result in ischemic hepato-necrosis, while it can also result in clinically inapparent transaminasemia. Marijuana and opiates, despite being associated with numerous deleterious effects, are rarely implicated in clinically apparent liver injury. Individuals with substance use disorder are also prone to viral hepatitis and hepatic insults secondary to hypotension, hypoxia, and other systemic ailments. Liver transplant candidacy in individuals with substance use disorder is a highly complex arena, with guidelines balancing abstinence requirements against evolving evidence on outcomes. This review article provides a thorough analysis of the hepatotoxic repercussions stemming from the agents commonly implicated in substance abuse disorders.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"34-40"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of hepatorenal syndrome incidence and outcomes using previous and current diagnostic criteria in cirrhotic patients. 肝硬化患者肝肾综合征发生率和预后的比较。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2025-01-01 DOI: 10.14744/hf.2023.2023.0067
Muhammet Mikdat Akbas, Mehmet Uzunlulu, Cundullah Torun, Ozgur Bahadir

Background and aim: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis with evolving diagnostic criteria. This study aimed to examine HRS prevalence, subtypes, and outcomes while comparing previous and current diagnostic criteria.

Materials and methods: This is a retrospective observational clinical study conducted on hospitalized patients with decompensated cirrhosis. Demographic characteristics, comorbidities, disease duration, disease severity, length of hospitalization, number of rehospitalizations, cirrhosis etiologies, laboratory data, and clinical outcomes were reviewed. The criteria from 2007 by the International Club of Ascites were the previous ones, with the 2015 criteria being the current criteria for diagnosing HRS. The incidence of HRS and its subtypes was determined, and the clinical characteristics of patients with and without HRS were compared using the Mann-Whitney U test.

Results: The study enrolled 212 patients, with a male predominance (57.5%) and a mean age of 63.4±14.5 years. A total of 32.1% of patients developed acute kidney injury (AKI), with prerenal azotemia being the most common type (76.5%), followed by intrinsic renal AKI (23.5%). Under the current criteria, 27 patients (12.7%) received an HRS diagnosis, while under the previous criteria, 16 patients (7.5%) received an HRS diagnosis, and the difference in diagnostic frequencies was statistically significant (p=0.046). In HRS cases, the MELD score (p=0.001), being classified as Child-Pugh C (p=0.043), rehospitalization (p=0.011), requiring intensive care (p=0.001), and creatinine levels (p<0.001) were higher.

Conclusion: AKI is common in hospitalized cirrhotic patients. The current HRS criteria identify more cases that need close monitoring compared to the previous criteria.

背景与目的:肝肾综合征(HRS)是肝硬化的一种严重并发症,诊断标准不断发展。本研究旨在检查HRS的患病率、亚型和结果,同时比较以前和现在的诊断标准。材料与方法:对住院失代偿期肝硬化患者进行回顾性观察性临床研究。回顾了人口统计学特征、合并症、病程、疾病严重程度、住院时间、再住院次数、肝硬化病因、实验室数据和临床结果。国际腹水俱乐部2007年的标准为以前的标准,2015年的标准为目前的HRS诊断标准。确定HRS的发病率及其亚型,并采用Mann-Whitney U检验比较有无HRS患者的临床特征。结果:212例患者入组,男性占57.5%,平均年龄63.4±14.5岁。共有32.1%的患者发生急性肾损伤(AKI),其中最常见的是肾性氮血症(76.5%),其次是内源性肾性AKI(23.5%)。现行标准下HRS诊断27例(12.7%),旧标准下HRS诊断16例(7.5%),诊断频次差异有统计学意义(p=0.046)。在HRS病例中,MELD评分(p=0.001)分为Child-Pugh C (p=0.043)、再住院(p=0.011)、需要重症监护(p=0.001)和肌酐水平(p)。结论:AKI在住院肝硬化患者中很常见。与以前的标准相比,目前的HRS标准确定了更多需要密切监测的病例。
{"title":"Comparison of hepatorenal syndrome incidence and outcomes using previous and current diagnostic criteria in cirrhotic patients.","authors":"Muhammet Mikdat Akbas, Mehmet Uzunlulu, Cundullah Torun, Ozgur Bahadir","doi":"10.14744/hf.2023.2023.0067","DOIUrl":"https://doi.org/10.14744/hf.2023.2023.0067","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis with evolving diagnostic criteria. This study aimed to examine HRS prevalence, subtypes, and outcomes while comparing previous and current diagnostic criteria.</p><p><strong>Materials and methods: </strong>This is a retrospective observational clinical study conducted on hospitalized patients with decompensated cirrhosis. Demographic characteristics, comorbidities, disease duration, disease severity, length of hospitalization, number of rehospitalizations, cirrhosis etiologies, laboratory data, and clinical outcomes were reviewed. The criteria from 2007 by the International Club of Ascites were the previous ones, with the 2015 criteria being the current criteria for diagnosing HRS. The incidence of HRS and its subtypes was determined, and the clinical characteristics of patients with and without HRS were compared using the Mann-Whitney U test.</p><p><strong>Results: </strong>The study enrolled 212 patients, with a male predominance (57.5%) and a mean age of 63.4±14.5 years. A total of 32.1% of patients developed acute kidney injury (AKI), with prerenal azotemia being the most common type (76.5%), followed by intrinsic renal AKI (23.5%). Under the current criteria, 27 patients (12.7%) received an HRS diagnosis, while under the previous criteria, 16 patients (7.5%) received an HRS diagnosis, and the difference in diagnostic frequencies was statistically significant (p=0.046). In HRS cases, the MELD score (p=0.001), being classified as Child-Pugh C (p=0.043), rehospitalization (p=0.011), requiring intensive care (p=0.001), and creatinine levels (p<0.001) were higher.</p><p><strong>Conclusion: </strong>AKI is common in hospitalized cirrhotic patients. The current HRS criteria identify more cases that need close monitoring compared to the previous criteria.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"5-10"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phenoconversion and in vivo phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy. 肝细胞色素P450的表型转化和体内表型:预测精准医学和个性化治疗的意义。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2025-01-01 DOI: 10.14744/hf.2023.2023.0047
Shakir Ali, Cem Aygun, Ibrahim Halil Bahcecioglu

Drug dose efficacy/toxicity depends on a number of factors including genetic and nongenetic factors, a pre-existing disease, and coadministration of other substances and drugs. Cytochrome P450 (CYP) proteins play a crucial role in drug metabolism where they catalyse a number of Phase I oxidation reactions. Concurrently administered drugs and substances, besides the CYP genotype are crucial and can induce/inhibit the CYP activity, thus affecting drug biotransformation and its bioavailability, compromising with drug efficacy, or even causing toxicity due to slow metabolism. Hepatic CYP is particularly important as it metabolizes about ¾ of all drugs. Determining the metabolite/drug ratio (in vivo CYP phenotyping) can be an important tool that can help in drug dose optimization for the drugs metabolized by specific CYPs as the genotype may not always reflect the true enzyme activity. Clinically important CYP isoforms commonly reported in drug oxidation reactions and which mainly include CYP3A4/5, CYP2C19, CYP2C9 and CYP2D6 need to be analysed for their activity in vivo, in at least the cases of unpredictable treatment outcomes. The activity levels of other less commonly reported but no less important CYPs, such as CYP2B6, one of the most polymorphic human CYP involved in the metabolism of artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine and methadone, and reported for its high inter-individuals and within-individual variability may also be determined on a case-to-case basis. This review highlights the variations in CYP activity due to various reasons and the importance of in vivo phenotyping over genotype in ascertaining drug bioavailability and dose optimization, implicating metabolite/drug ratio determination for personalized treatment of especially chronic liver disease patients.

药物剂量效力/毒性取决于许多因素,包括遗传和非遗传因素、先前存在的疾病以及其他物质和药物的共同给药。细胞色素P450 (CYP)蛋白在药物代谢中起着至关重要的作用,它们催化了许多I期氧化反应。除了CYP基因型外,同时给药的药物和物质也很重要,它们可以诱导/抑制CYP活性,从而影响药物的生物转化及其生物利用度,影响药物的疗效,甚至因代谢缓慢而产生毒性。肝脏CYP尤其重要,因为它代谢约3 / 4的药物。确定代谢物/药物比(体内CYP表型)是一个重要的工具,可以帮助特定CYP代谢的药物优化剂量,因为基因型可能并不总是反映真实的酶活性。通常在药物氧化反应中报道的临床重要的CYP亚型,主要包括CYP3A4/5、CYP2C19、CYP2C9和CYP2D6,至少在治疗结果不可预测的情况下,需要分析它们在体内的活性。其他不常报道但同样重要的CYP的活性水平,如CYP2B6,它是最具多态性的人类CYP之一,参与青蒿素、安非他酮、环磷酰胺、依非韦伦、氯胺酮和美沙酮的代谢,并因其高个体间和个体内变异性而被报道,也可根据具体情况确定。这篇综述强调了由于各种原因导致的CYP活性的变化,以及体内表型比基因型在确定药物生物利用度和剂量优化方面的重要性,这意味着代谢物/药物比的确定对于个性化治疗特别是慢性肝病患者的重要性。
{"title":"Phenoconversion and <i>in vivo</i> phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy.","authors":"Shakir Ali, Cem Aygun, Ibrahim Halil Bahcecioglu","doi":"10.14744/hf.2023.2023.0047","DOIUrl":"10.14744/hf.2023.2023.0047","url":null,"abstract":"<p><p>Drug dose efficacy/toxicity depends on a number of factors including genetic and nongenetic factors, a pre-existing disease, and coadministration of other substances and drugs. Cytochrome P450 (CYP) proteins play a crucial role in drug metabolism where they catalyse a number of Phase I oxidation reactions. Concurrently administered drugs and substances, besides the CYP genotype are crucial and can induce/inhibit the CYP activity, thus affecting drug biotransformation and its bioavailability, compromising with drug efficacy, or even causing toxicity due to slow metabolism. Hepatic CYP is particularly important as it metabolizes about ¾ of all drugs. Determining the metabolite/drug ratio (<i>in vivo</i> CYP phenotyping) can be an important tool that can help in drug dose optimization for the drugs metabolized by specific CYPs as the genotype may not always reflect the true enzyme activity. Clinically important CYP isoforms commonly reported in drug oxidation reactions and which mainly include CYP3A4/5, CYP2C19, CYP2C9 and CYP2D6 need to be analysed for their activity <i>in vivo</i>, in at least the cases of unpredictable treatment outcomes. The activity levels of other less commonly reported but no less important CYPs, such as CYP2B6, one of the most polymorphic human CYP involved in the metabolism of artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine and methadone, and reported for its high inter-individuals and within-individual variability may also be determined on a case-to-case basis. This review highlights the variations in CYP activity due to various reasons and the importance of <i>in vivo</i> phenotyping over genotype in ascertaining drug bioavailability and dose optimization, implicating metabolite/drug ratio determination for personalized treatment of especially chronic liver disease patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"121-128"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leflunomide induced fatal dress syndrome need liver transplantation. 来氟米特诱发的致命着装综合征需要肝移植。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2024.2024.0010
Ali Riza Caliskan, Mehmet Ali Erdogan

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening, drug-induced hypersensitivity reaction that involves hematological abnormalities (atypical lymphocytosis, eosinophilia), lymphadenopathy, skin eruption, and internal organ involvement (lung, liver, kidney). The 36-year-old female patient was followed by bloody diarrhea, diffuse skin rashes and hepatitis. She was diagnosed with psoriatic arthritis, and Leflunomide 20 mg was added to the treatment six weeks ago. Upon developing hepatic encephalopathy and deepening the fulminant liver failure during the follow-up, a living donor liver from her son was transplanted on the 4th day of hospitalization. The patient had deceased on the second day after liver transplantation due to multiple organ failures. In the literature, mortality in DRESS syndrome is mostly secondary to hepatic failure. Liver transplantation cannot be effective due to systemic involvement and recurrence in the transplanted liver.

嗜酸性粒细胞增多和全身症状药物反应(DRESS)综合征是一种严重的、可能危及生命的药物超敏反应,包括血液学异常(非典型淋巴细胞增多、嗜酸性粒细胞增多)、淋巴结病、皮肤糜烂和内脏器官受累(肺、肝、肾)。这名 36 岁的女性患者随后出现血性腹泻、弥漫性皮疹和肝炎。她被诊断为银屑病关节炎,六周前开始在治疗中添加来氟米特 20 毫克。在随访期间出现肝性脑病并加深了暴发性肝衰竭,住院第 4 天移植了她儿子的活体肝脏。患者在肝移植后第二天因多器官功能衰竭而死亡。在文献中,DRESS 综合征的死亡率大多继发于肝功能衰竭。由于全身受累和移植肝脏复发,肝移植无法奏效。
{"title":"Leflunomide induced fatal dress syndrome need liver transplantation.","authors":"Ali Riza Caliskan, Mehmet Ali Erdogan","doi":"10.14744/hf.2024.2024.0010","DOIUrl":"10.14744/hf.2024.2024.0010","url":null,"abstract":"<p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening, drug-induced hypersensitivity reaction that involves hematological abnormalities (atypical lymphocytosis, eosinophilia), lymphadenopathy, skin eruption, and internal organ involvement (lung, liver, kidney). The 36-year-old female patient was followed by bloody diarrhea, diffuse skin rashes and hepatitis. She was diagnosed with psoriatic arthritis, and Leflunomide 20 mg was added to the treatment six weeks ago. Upon developing hepatic encephalopathy and deepening the fulminant liver failure during the follow-up, a living donor liver from her son was transplanted on the 4<sup>th</sup> day of hospitalization. The patient had deceased on the second day after liver transplantation due to multiple organ failures. In the literature, mortality in DRESS syndrome is mostly secondary to hepatic failure. Liver transplantation cannot be effective due to systemic involvement and recurrence in the transplanted liver.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"204-206"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intrabiliary pressure in the pathophysiology of extra hepatic biliary obstruction. 肝外胆道梗阻病理生理学中的胆道内压。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0066
Dhananjay Saxena, Shridhar Vasantrao Sasturkar, Amar Mukund, Yashwant Patidar, Ashok Kumar Choudhury, Ragini Kilambi, Pratibha Kale

Background and aim: The aim of this study was to evaluate the role of intrabiliary pressure (IBP) in the pathophysiology of extrahepatic biliary obstruction (EHBO) during percutaneous transhepatic biliary drainage (PTBD).

Materials and methods: Adult patients with EHBO who underwent PTBD were prospectively enrolled. IBP was recorded during primary PTBD. The parameters of interest were age, gender, etiology of EHBO, baseline and post-PTBD liver function tests, duration for resolution of jaundice (decrease in total serum bilirubin ≥30% of baseline or <2 mg/dL), cholangitis, bile cultures, and serum albumin levels. The level of EHBO was divided into three types: Type 1 - secondary biliary confluence involved; Type 2 - primary biliary confluence involved; Type 3 - mid and distal common bile duct obstruction.

Results: IBP was measured in 102 patients, and finally, 87 patients, including 52 (59.77%) females, were analyzed. The mean age of the patients was 56.1±11.6 years. The most common etiology of EHBO was carcinoma of the gallbladder in 44 (50.6%) patients. The mean IBP was 18.41±3.91 mmHg. IBP was significantly higher in Type 3 EHBO compared to Type 1 and 2 (p=0.012). A significant correlation was seen between IBP and baseline total serum bilirubin (p<0.01). There was a negative correlation between IBP and baseline serum albumin (p=0.017). In 56.3% of patients, resolution of jaundice was observed by day 3, but this was not significantly associated with IBP (p=0.19). There was no correlation between IBP and cholangitis (p=0.97) or bacterial cultures (p=0.21).

Conclusion: IBP was significantly associated with the type of EHBO, baseline serum bilirubin, and albumin levels. IBP could not predict cholangitis or the resolution of jaundice after PTBD.

背景和目的:本研究旨在评估胆道内压力(IBP)在经皮经肝胆道引流术(PTBD)期间肝外胆道梗阻(EHBO)病理生理学中的作用:对接受经皮经肝胆道引流术(PTBD)的肝外胆道梗阻(EHBO)成人患者进行前瞻性研究。经皮经肝胆管引流术(PTBD)期间记录 IBP。相关参数包括年龄、性别、EHBO病因、基线和PTBD后肝功能检查、黄疸消退持续时间(血清总胆红素下降≥基线的30%或结果):对 102 名患者的 IBP 进行了测量,最后分析了 87 名患者,包括 52 名女性(59.77%)。患者的平均年龄为(56.1±11.6)岁。EHBO 最常见的病因是胆囊癌,有 44 例(50.6%)患者。平均 IBP 为 18.41±3.91 mmHg。3 型 EHBO 的 IBP 明显高于 1 型和 2 型(P=0.012)。IBP 与基线血清总胆红素之间存在明显相关性(p结论:IBP与EHBO类型、基线血清胆红素和白蛋白水平有明显相关性。IBP 无法预测胆管炎或 PTBD 后黄疸的消退。
{"title":"Intrabiliary pressure in the pathophysiology of extra hepatic biliary obstruction.","authors":"Dhananjay Saxena, Shridhar Vasantrao Sasturkar, Amar Mukund, Yashwant Patidar, Ashok Kumar Choudhury, Ragini Kilambi, Pratibha Kale","doi":"10.14744/hf.2023.2023.0066","DOIUrl":"10.14744/hf.2023.2023.0066","url":null,"abstract":"<p><strong>Background and aim: </strong>The aim of this study was to evaluate the role of intrabiliary pressure (IBP) in the pathophysiology of extrahepatic biliary obstruction (EHBO) during percutaneous transhepatic biliary drainage (PTBD).</p><p><strong>Materials and methods: </strong>Adult patients with EHBO who underwent PTBD were prospectively enrolled. IBP was recorded during primary PTBD. The parameters of interest were age, gender, etiology of EHBO, baseline and post-PTBD liver function tests, duration for resolution of jaundice (decrease in total serum bilirubin ≥30% of baseline or <2 mg/dL), cholangitis, bile cultures, and serum albumin levels. The level of EHBO was divided into three types: Type 1 - secondary biliary confluence involved; Type 2 - primary biliary confluence involved; Type 3 - mid and distal common bile duct obstruction.</p><p><strong>Results: </strong>IBP was measured in 102 patients, and finally, 87 patients, including 52 (59.77%) females, were analyzed. The mean age of the patients was 56.1±11.6 years. The most common etiology of EHBO was carcinoma of the gallbladder in 44 (50.6%) patients. The mean IBP was 18.41±3.91 mmHg. IBP was significantly higher in Type 3 EHBO compared to Type 1 and 2 (p=0.012). A significant correlation was seen between IBP and baseline total serum bilirubin (p<0.01). There was a negative correlation between IBP and baseline serum albumin (p=0.017). In 56.3% of patients, resolution of jaundice was observed by day 3, but this was not significantly associated with IBP (p=0.19). There was no correlation between IBP and cholangitis (p=0.97) or bacterial cultures (p=0.21).</p><p><strong>Conclusion: </strong>IBP was significantly associated with the type of EHBO, baseline serum bilirubin, and albumin levels. IBP could not predict cholangitis or the resolution of jaundice after PTBD.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"198-203"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Action of melatonin and physical exercise on the liver of cirrhotic rats: Study of oxidative stress and the inflammatory process. 褪黑激素和体育锻炼对肝硬化大鼠肝脏的作用:氧化应激和炎症过程研究
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0037
Gabriela S Martins, Carlos Gustavo S Rosa, Elizangela G Schemitt, Josieli R Colares, Sandielly Rb Fonseca, Marilda S Brasil, Millena O Engeroff, Norma P Marroni

Background and aim: Cirrhosis is characterized by structural and functional alterations of the liver. Melatonin (MLT) has antioxidant properties. Physical exercise (EX) can reverse muscle loss in cirrhotic patients. The objective was to evaluate the action of MLT and EX on the liver of rats subjected to the experimental model of bile duct ligation (BLD).

Materials and methods: 48 male Wistar rats were used, divided into groups: Control (CO), CO+MLT, CO+EX, CO+MLT+EX, BDL, BDL+MLT, BDL+EX, and BDL+MLT+EX. The treatments occurred from the 15th to the 28th day. The dose of MLT was 20 mg/kg via I.p (1x/day), and the EX was performed 10 min/day. Blood and liver were collected for analysis.

Results: The liver integrity enzymes AST, ALT, and ALP showed a significant reduction in the groups treated with MLT and EX. Histological analyses showed reorganization of the liver parenchyma, reduction of inflammatory infiltrate, and fibrotic nodules. Lipoperoxidation (LPO), the activity of antioxidant enzymes, and nitric oxide metabolites showed a significant reduction in the groups treated with MLT and EX. The expression of TNF-α and NF-kB decreased in the treated groups.

Conclusion: Melatonin and physical exercise seem to be effective in restoring the parameters evaluated in this model of experimental cirrhosis.

背景和目的:肝硬化以肝脏结构和功能改变为特征。褪黑素(MLT)具有抗氧化作用。体育锻炼(EX)可逆转肝硬化患者的肌肉损失。材料和方法:使用 48 只雄性 Wistar 大鼠,分为对照组(CO)、CO+MLT 组(CO+MLT 组)和 EX 组(EX 组):对照组(CO)、CO+MLT 组、CO+EX 组、CO+MLT+EX 组、BDL 组、BDL+MLT 组、BDL+EX 组和 BDL+MLT+EX 组。治疗时间为第 15 天至第 28 天。MLT的剂量为20毫克/千克,经静脉注射(1次/天),EX的剂量为10分钟/天。采集血液和肝脏进行分析:结果:接受 MLT 和 EX 治疗组的肝脏完整性酶 AST、ALT 和 ALP 显著降低。组织学分析表明,肝实质重组,炎症浸润和纤维化结节减少。脂肪过氧化(LPO)、抗氧化酶活性和一氧化氮代谢物在接受 MLT 和 EX 治疗的组别中显著减少。结论:结论:褪黑素和体育锻炼似乎能有效恢复实验性肝硬化模型中的评估指标。
{"title":"Action of melatonin and physical exercise on the liver of cirrhotic rats: Study of oxidative stress and the inflammatory process.","authors":"Gabriela S Martins, Carlos Gustavo S Rosa, Elizangela G Schemitt, Josieli R Colares, Sandielly Rb Fonseca, Marilda S Brasil, Millena O Engeroff, Norma P Marroni","doi":"10.14744/hf.2023.2023.0037","DOIUrl":"10.14744/hf.2023.2023.0037","url":null,"abstract":"<p><strong>Background and aim: </strong>Cirrhosis is characterized by structural and functional alterations of the liver. Melatonin (MLT) has antioxidant properties. Physical exercise (EX) can reverse muscle loss in cirrhotic patients. The objective was to evaluate the action of MLT and EX on the liver of rats subjected to the experimental model of bile duct ligation (BLD).</p><p><strong>Materials and methods: </strong>48 male Wistar rats were used, divided into groups: Control (CO), CO+MLT, CO+EX, CO+MLT+EX, BDL, BDL+MLT, BDL+EX, and BDL+MLT+EX. The treatments occurred from the 15<sup>th</sup> to the 28<sup>th</sup> day. The dose of MLT was 20 mg/kg via I.p (1x/day), and the EX was performed 10 min/day. Blood and liver were collected for analysis.</p><p><strong>Results: </strong>The liver integrity enzymes AST, ALT, and ALP showed a significant reduction in the groups treated with MLT and EX. Histological analyses showed reorganization of the liver parenchyma, reduction of inflammatory infiltrate, and fibrotic nodules. Lipoperoxidation (LPO), the activity of antioxidant enzymes, and nitric oxide metabolites showed a significant reduction in the groups treated with MLT and EX. The expression of TNF-α and NF-kB decreased in the treated groups.</p><p><strong>Conclusion: </strong>Melatonin and physical exercise seem to be effective in restoring the parameters evaluated in this model of experimental cirrhosis.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"184-192"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of triglyceride-glucose index and anthropometric obesity indices in predicting severe grades of hepatic steatosis in nonalcoholic fatty liver disease among non-diabetic obese individuals. 甘油三酯-葡萄糖指数与人体测量肥胖指数在预测非糖尿病肥胖者非酒精性脂肪肝肝脂肪变性严重程度方面的比较。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-02 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0049
Huseyin Karaaslan, Hasan Inan, Alper Tunga Turkmen, Ismail Altintas, Nida Uyar, Mehmet Ali Eren

Background and aim: The triglyceride glucose index (TyG) has been proposed as a promising indicator of both insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). However, the efficacy of the TyG index in predicting NAFLD has not been adequately studied, particularly in obese individuals.

Materials and methods: We analyzed 190 morbidly obese individuals. The TyG index, anthropometric obesity indices, homeostatic model assessment (HOMA-IR), and biochemical parameters were compared. NAFLD was diagnosed by hepatic ultrasonography and classified into four grades (0, 1, 2, and 3). Individuals in grades 2 and 3 are considered to have severe steatosis, while those in grades 0 and 1 do not.

Results: The area under the curve (AUC) values of the TyG index, body mass index, neck circumferences, waist-to-hip ratio, and HOMA-IR did not differ significantly in predicting severe steatosis (0.640, 0.742, 0.725, 0.620, and 0.624 respectively). However, the AUC values of waist circumference and alanine aminotransferase provided better predictions than the TyG index (0.782, 0.744, and 0.640 respectively).

Conclusion: The TyG index is highly effective in predicting both the presence and severity of NAFLD. However, it did not outperform simple obesity indices in predicting NAFLD and its severity in obese patients.

背景和目的:甘油三酯血糖指数(TyG)已被认为是胰岛素抵抗(IR)和非酒精性脂肪肝(NAFLD)的可靠指标。然而,TyG 指数在预测非酒精性脂肪肝方面的功效尚未得到充分研究,尤其是在肥胖人群中:我们对 190 名病态肥胖者进行了分析。对 TyG 指数、人体测量肥胖指数、稳态模型评估(HOMA-IR)和生化参数进行了比较。非酒精性脂肪肝通过肝脏超声波检查确诊,并分为四级(0、1、2 和 3)。2级和3级的人被认为有严重的脂肪变性,而0级和1级的人则没有:TyG指数、体重指数、颈围、腰臀比和HOMA-IR的曲线下面积(AUC)值在预测严重脂肪变性方面没有显著差异(分别为0.640、0.742、0.725、0.620和0.624)。然而,腰围和丙氨酸氨基转移酶的 AUC 值比 TyG 指数的预测效果更好(分别为 0.782、0.744 和 0.640):结论:TyG指数能有效预测非酒精性脂肪肝的存在和严重程度。结论:TyG 指数在预测是否存在非酒精性脂肪肝及其严重程度方面非常有效,但在预测肥胖患者的非酒精性脂肪肝及其严重程度方面,它并不优于简单的肥胖指数。
{"title":"Comparison of triglyceride-glucose index and anthropometric obesity indices in predicting severe grades of hepatic steatosis in nonalcoholic fatty liver disease among non-diabetic obese individuals.","authors":"Huseyin Karaaslan, Hasan Inan, Alper Tunga Turkmen, Ismail Altintas, Nida Uyar, Mehmet Ali Eren","doi":"10.14744/hf.2023.2023.0049","DOIUrl":"10.14744/hf.2023.2023.0049","url":null,"abstract":"<p><strong>Background and aim: </strong>The triglyceride glucose index (TyG) has been proposed as a promising indicator of both insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). However, the efficacy of the TyG index in predicting NAFLD has not been adequately studied, particularly in obese individuals.</p><p><strong>Materials and methods: </strong>We analyzed 190 morbidly obese individuals. The TyG index, anthropometric obesity indices, homeostatic model assessment (HOMA-IR), and biochemical parameters were compared. NAFLD was diagnosed by hepatic ultrasonography and classified into four grades (0, 1, 2, and 3). Individuals in grades 2 and 3 are considered to have severe steatosis, while those in grades 0 and 1 do not.</p><p><strong>Results: </strong>The area under the curve (AUC) values of the TyG index, body mass index, neck circumferences, waist-to-hip ratio, and HOMA-IR did not differ significantly in predicting severe steatosis (0.640, 0.742, 0.725, 0.620, and 0.624 respectively). However, the AUC values of waist circumference and alanine aminotransferase provided better predictions than the TyG index (0.782, 0.744, and 0.640 respectively).</p><p><strong>Conclusion: </strong>The TyG index is highly effective in predicting both the presence and severity of NAFLD. However, it did not outperform simple obesity indices in predicting NAFLD and its severity in obese patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 3","pages":"113-119"},"PeriodicalIF":1.2,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients. 针对偶发性抗线粒体 M2 抗体阳性患者的最佳检测策略。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-02 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2024.2024.0007
Ilkay Ergenc, Busra Gozaydinoglu, Caglayan Keklikkiran, Yusuf Yilmaz
{"title":"Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients.","authors":"Ilkay Ergenc, Busra Gozaydinoglu, Caglayan Keklikkiran, Yusuf Yilmaz","doi":"10.14744/hf.2024.2024.0007","DOIUrl":"10.14744/hf.2024.2024.0007","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 3","pages":"165-166"},"PeriodicalIF":1.2,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepatology Forum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1